Payment overview · 2025
General Payments
$330.09
16 reported records · 7 companies
Healthcare provider profile · identity verified
Mark James Elder, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · JAY, FL · NPI 1477559409
Verified facts
What the public records show
CMS Open Payments records show Mark James Elder, D.O. received $330.09 in general payments during 2025 across 16 reported records.
Novo Nordisk Inc accounted for 27.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Ozempic, Rexulti, Rybelsus, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ubrelvy by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Myrbetriq by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $89.71 | 27.2% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $88.44 | 26.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $72.19 | 21.9% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.15 | 7.0% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.28 | 6.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.63 | 5.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $16.69 | 5.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $330.09 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $89.71 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $88.44 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $75.88 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $25.91 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.15 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $13.78 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $13.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 77 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 60 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
77 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
60 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 838 | 118 |
| Atorvastatin Calcium | Atorvastatin Calcium | 685 | 109 |
| Lisinopril | Lisinopril | 557 | 121 |
| Potassium Chloride | Potassium Chloride | 538 | 86 |
| Gabapentin | Gabapentin | 489 | 73 |
| Levothyroxine Sodium | Levothyroxine Sodium | 427 | 66 |
| Omeprazole | Omeprazole | 416 | 98 |
| Furosemide | Furosemide | 412 | 70 |
| Tramadol Hcl | Tramadol Hcl | 406 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 373 | 57 |
| Pregabalin | Pregabalin | 311 | 49 |
| Losartan Potassium | Losartan Potassium | 302 | 54 |
| Trazodone Hcl | Trazodone Hcl | 272 | 37 |
| Eliquis | Apixaban | 248 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 221 | 40 |
| Donepezil Hcl | Donepezil Hcl | 218 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 210 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 210 | 48 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 205 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 198 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 196 | 55 |
| Clopidogrel | Clopidogrel Bisulfate | 187 | 42 |
| Sertraline Hcl | Sertraline Hcl | 187 | 26 |
| Famotidine | Famotidine | 177 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 174 | 56 |
| Prednisone | Prednisone | 173 | 114 |
| Alprazolam | Alprazolam | 166 | 23 |
| Baclofen | Baclofen | 162 | 36 |
| Montelukast Sodium | Montelukast Sodium | 160 | 40 |
| Metformin Hcl | Metformin Hcl | 159 | 34 |
| Glipizide | Glipizide | 149 | 20 |
| Promethazine Hcl | Promethazine Hcl | 145 | 38 |
| Fenofibrate | Fenofibrate | 142 | 20 |
| Celecoxib | Celecoxib | 140 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 135 | 30 |
| Meloxicam | Meloxicam | 127 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 124 | 32 |
| Carvedilol | Carvedilol | 121 | 35 |
| Clonidine Hcl | Clonidine Hcl | 117 | 36 |
| Memantine Hcl | Memantine Hcl | 117 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 112 | 15 |
| Farxiga | Dapagliflozin Propanediol | 110 | 23 |
| Allopurinol | Allopurinol | 109 | 18 |
| Cephalexin | Cephalexin | 106 | 89 |
| Oxybutynin Chloride | Oxybutynin Chloride | 106 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 101 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 101 | 21 |
| Divalproex Sodium | Divalproex Sodium | 100 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 99 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 97 | 19 |
| Methocarbamol | Methocarbamol | 96 | 13 |
| Alendronate Sodium | Alendronate Sodium | 91 | 20 |
| Xarelto | Rivaroxaban | 90 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 18 |
| Azithromycin | Azithromycin | 89 | 83 |
| Amitriptyline Hcl | Amitriptyline Hcl | 87 | 18 |
| Lorazepam | Lorazepam | 86 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 85 | 26 |
| Mirtazapine | Mirtazapine | 84 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 81 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 77 | 28 |
| Linzess | Linaclotide | 77 | 17 |
| Ventolin Hfa | Albuterol Sulfate | 74 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 72 | 22 |
| Simvastatin | Simvastatin | 71 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | suppressed |
| Spironolactone | Spironolactone | 68 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 68 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | suppressed |
| Topiramate | Topiramate | 66 | 13 |
| Clonazepam | Clonazepam | 64 | 12 |
| Finasteride | Finasteride | 63 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 62 | 51 |
| Ondansetron Odt | Ondansetron | 62 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | suppressed |
| Levetiracetam | Levetiracetam | 60 | suppressed |
| Ozempic | Semaglutide | 60 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 19 |
| Ibuprofen | Ibuprofen | 59 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 58 | suppressed |
| Trulicity | Dulaglutide | 58 | 15 |
| Buspirone Hcl | Buspirone Hcl | 57 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 56 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 56 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 56 | 20 |
| Sucralfate | Sucralfate | 56 | 18 |
| Diazepam | Diazepam | 53 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | suppressed |
| Fluconazole | Fluconazole | 51 | 34 |
| Ropinirole Hcl | Ropinirole Hcl | 51 | 11 |
| Bumetanide | Bumetanide | 50 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 49 | 18 |
| Atenolol | Atenolol | 48 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | suppressed |
| Eszopiclone | Eszopiclone | 45 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 44 | 14 |
| Ezetimibe | Ezetimibe | 43 | 13 |
| Mupirocin | Mupirocin | 42 | 28 |
| Ibandronate Sodium | Ibandronate Sodium | 41 | 14 |
| Nystatin | Nystatin | 41 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | suppressed |
| Mounjaro | Tirzepatide | 38 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 28 |
| Humalog Kwikpen U-100 | Insulin Lispro | 37 | 13 |
| Januvia | Sitagliptin Phosphate | 37 | 11 |
| Nitroglycerin | Nitroglycerin | 37 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 13 |
| Rybelsus | Semaglutide | 35 | suppressed |
| Gemfibrozil | Gemfibrozil | 34 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 34 | suppressed |
| Tradjenta | Linagliptin | 34 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 31 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Glimepiride | Glimepiride | 31 | suppressed |
| Lactulose | Lactulose | 31 | 13 |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Temazepam | Temazepam | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Latanoprost | Latanoprost | 30 | suppressed |
| Novolog | Insulin Aspart | 30 | suppressed |
| Rexulti | Brexpiprazole | 30 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 29 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 12 |
| Dexamethasone | Dexamethasone | 29 | 28 |
| Phenobarbital | Phenobarbital | 29 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Sotalol | Sotalol Hcl | 28 | suppressed |
| Loperamide | Loperamide Hcl | 27 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Cilostazol | Cilostazol | 25 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 25 | suppressed |
| Clonidine | Clonidine | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | 11 |
| Levemir | Insulin Detemir | 23 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Ibu | Ibuprofen | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Letrozole | Letrozole | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Ubrelvy | Ubrogepant | 15 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 14 | suppressed |
| Klor-Con 10 | Potassium Chloride | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $330.09 · 16 records | Novo Nordisk Inc | CREON, Dexcom G6 Transmitter, INSPIRE, LINZESS, Ozempic, QULIPTA, REXULTI, Rybelsus, UBRELVY, VRAYLAR, Veozah | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error